New combo aims to tackle Hard-to-Treat leukemia
NCT ID NCT07635485
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a two-drug combination (venetoclax and azacitidine) followed by a stem cell transplant can help people with a rare, hard-to-treat form of acute myeloid leukemia (AML). The trial will enroll 50 adults who have not been treated before. The goal is to see if this approach improves survival and leads to complete remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- venetoclax and azacitidine
- What this could lead to
- If successful, this combination followed by a stem cell transplant could offer a more effective treatment path for people with hard-to-treat AML, potentially improving survival and remission rates.
- What could go wrong
- This is an early-stage, single-arm study with only 50 participants, so results may not apply broadly. The transplant procedure carries serious risks, including infection and graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPLASTIC ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a liposomal chemo combo outsmart tough leukemias?
- Can a Platelet-Boosting drug speed recovery for older leukemia patients?
- Radioactive antibody hones in on cancer cells to boost transplant success
- New drug cocktail shows promise for Tough-to-Treat leukemia in seniors
- Could a Gene-Targeting drug boost chemo for older leukemia patients?